Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) Trial: Rationale and design

详细信息    查看全文

• 作者：Paul S. Myles ; Kate Leslie ; Philip Peyton ; Michael Paech ; Andrew Forbes ; Matthew T.V. Chan ; Daniel Sessler ; Philip J. Devereaux ; Brendan S. Silbert ; Konrad Jamrozik ; Scott Beattie ; Neal Badner ; James Tomlinson ; Sophia Wallace ; the ANZCA Trials Group
• 刊名：American Heart Journal
• 出版年：2009
• 出版时间：March 2009
• 年：2009
• 卷：157
• 期：3
• 页码：488-494.e1
• 全文大小：159 K

文摘

Background

Globally there are >200 million major surgical procedures undertaken annually, and about 20 % of these involve patients who have coronary artery disease. Many receive nitrous oxide, which impairs methionine synthase, thus inhibiting folate synthesis and increasing postoperative homocysteine levels. Nitrous oxide anesthesia leads to postoperative endothelial dysfunction, and there is some evidence that it increases myocardial ischemia and, possibly, myocardial infarction. We have initiated the Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) Trial to test the hypothesis that in inpatients undergoing anesthesia for major noncardiac surgery, avoidance of nitrous oxide will reduce the incidence of death and major cardiovascular events.

Methods

ENIGMA-II is a 7,000-patient, international randomized trial involving patients at risk of coronary artery disease undergoing noncardiac surgery. The patients, health care providers (except for the anesthesiologists), data collectors, and outcome adjudicators are blinded to whether patients receive nitrous oxide–containing or nitrous oxide–free anesthetic. The primary outcome is a composite of death and major nonfatal events (ie, myocardial infarction, cardiac arrest, pulmonary embolism, and stroke) at 30 days after surgery.

Results

At present, ENIGMA-II has randomized >1,000 patients in 22 hospitals in 5 countries. To date, patients' mean age is 70 years, 66 % are men, 38 % have a history of coronary artery disease, 19 % have a history of cerebrovascular disease, and 84 % have a history of hypertension. Most patients have undergone intra-abdominal 28 % , vascular 32 % , and orthopedic 16 % surgery.

Conclusions

The ENIGMA-II Trial will be the largest study yet conducted to ascertain the benefits and risks of removing nitrous oxide from the gas mixture in anesthesia. The results of this large international trial will guide the clinical care of the hundreds of millions of adults undergoing noncardiac surgery annually.